Top Viewed Report: World generic market report 2013 by marketresearchreports.biz
Upcoming SlideShare
Loading in...5
×
 

Top Viewed Report: World generic market report 2013 by marketresearchreports.biz

on

  • 432 views

...


World Generic Market Report 2013
A complete global analysis of the prospects for markets and companies in this dynamic industry sector Features and benefits of this thoroughly-researched and highly-regarded management report:
To Read The Complete Report Kindly Visit: http://www.marketresearchreports.biz/analysis/170302
For All Latest Reports Kindly visit: http://www.marketresearchreports.biz

Statistics

Views

Total Views
432
Views on SlideShare
432
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Top Viewed Report: World generic market report 2013 by marketresearchreports.biz Top Viewed Report: World generic market report 2013 by marketresearchreports.biz Document Transcript

  • World Generic Market Report 2013 A complete global analysis of the prospects for markets and companies in this dynamic industry sector Features and benefits of this thoroughly-researched and highly-regarded management report: High quality research and forecasts: Independent research, combined with detailed 5-year forecasts, informed commentary and unrivalled primary source data will aid your business planning and decision-making process Global coverage - with 74 country markets profiles: Scope opportunities for new investment or sales growth, with detailed historical data and forecasts on the leading developed economies as well as key emerging markets from Africa, the Americas, Asia, Emerging Europe, and the Middle East Issue driven: Understand the latest company, product, and regulatory developments Company Insight - with the 26 leading companies reviewed: Who’s working with whom? Who’s suing whom? Who’s up, who’s down? Assess the activities, strategies and market position of your competitors, partners and clients Flexible formats: Available in pdf format with online access included in the price. Cost-effective distribution licences can ensure you get the best from your investment Biosimilars: Coverage of the fast developing biosimilars market Easily understand the threats and opportunities that are shaping this rapidly evolving sector! Industry Issues If the branded pharmaceutical industry was facing a patent cliff it is now teetering on the edge of it. Ironically, it is the world’s best selling drug, Lipitor, which exemplifies the trend. Despite still having patent protection, Pfizer has been unable to stem the tide of interest and pressure from a number of companies, Ranbaxy being chief amongst them. Despite pressure on prices in many markets, the generic sector continues to thrive with increased sales across the board in 2012. The maturity of the sector can also be seen in the size of the businesses: there are now 18 generic companies with revenues in excess of US$1,000 million, 6 more than in 2008/09.. Company Assessments In recent years there has been a trend towards consolidation, both within the generics industry itself, and between the generics industry and the branded industry. This has been a trend born of necessity, reflecting both the difficult economic environment and the slowdown in development of innovative drugs. Without doubt, the most important and largest acquisition to have taken place over the last year has been the merger between Watson Pharmaceuticals and Actavis. The merger has created a company with revenues for the year ended 31st December 2012 of just over US$5.9 billion. Market Analysis The generic market is experiencing two opposing trends driven by the global downturn. On one hand, the use of generics is increasing due to their cost-effectiveness and adoption has accelerated in markets where branded prescribing was dominant. On the other hand, the squeeze on government spending has not left generics untouched, with many countries lowering generic prices through cuts in reimbursement rates or contract tendering with a resultant squeeze on margins. Industry consolidation, new market opportunities, the latest on biosimilars plus much, much more! This leading report, now in its 11th year of publication, draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues. This extensive data set is interpreted and evaluated by the editors to provide a complete and compelling review of the whole sector. Key facts, issues and questions Which branded companies are taking an increased interest in the dynamic generics market? How are World Generic Market Report 2013
  • generics companies faring in the recession? Which companies are involved in the latest legal challenges and litigation? Biosimilars get ever closer – what are the latest regulatory updates? Which country markets have experienced the largest growth in 2012 and which are forecast to be the fastest growers? Negative perceptions of generic drug quality – which markets are most exposed? Pricing pressures – which markets are facing the greatest pressures on pricing from the government? State support for local production – which markets are set to benefit from increased government support? table Of Content foreword 1 the State Ofthe Industry 2 generic Consolidations, Mergers And Acquisitions .2 generic And Branded Acquisitions And Agreements 4 the Branded Industry’s ‘patent Cliff’ 6 major Generic Manufacturers .7 biosimilars .11 in The Usa 11 another Option: File A Full Bla? .11 the Development Of A Us Biosimilar Pathway 12 the Bcpia .13 implementation Of The Bcpia 13 fda Guidance Documents Published .15 innovators Make Their Case To The Fda 16 biosimilar User Fee Programme 18 virginia Passes Biosimilar Legislation .18 gpha: Grant Thornton Study Shows Need For Biosimilar Competition .20 in Europe .21 ema Guideline Documents .21 ema To Accept Biosimilar Reference Medicines From Outside The Eea 22 sandoz: New Study Shows Biosimilars Can Save Eu Healthcare Systems Up To 33 Billion Euros By 2020 23 elsewhere 24 current Issuesin The Usa 25 authorised Generics 25 fda Issues Direct Final Rule Regarding Listing Of Authorised Generics .26 pay For Delay Agreements .27 shared Exclusivity 27 gdufa 31 drug Shortages 32 generic Drug Labelling 33 study Finds Majority Of Generics’ Warning Labels Differ From Branded Equivalents .34 current Issuesin The European Union .36 ec Releases Final Report Into Pharmaceutical Sector 36 monitoring Of Patent Settlements 37 ec Statement Of Objections 38 european Parliament Votes In Favour Of European Unitary Patent 42 eu Committee Votes On Transparency Directive .42 World Generic Market Report 2013
  • free Trade Agreements 43 current Issuesin The Rest Ofthe World .44 the Wto And Access To Generics 44 trips Patent Ruling On Least-developed Countries, 2002 44 2003 Agreement 44 us Pepfar Programme 47 the Medicines Patent Pool .49 patent Laws .50 india 50 companies 53 actavis 53 introduction .53 company Details .53 watson Pharmaceuticals 53 actavis Group .54 acquisition And Merger 54 operations – Watson Pharmaceuticals .55 operations – Actavis .56 products .57 generics 57 brand Products 58 distribution 59 financials 63 segment Results . 64 recent Developments 65 recent Acquisitions .65 recent Company News 66 recent Litigation News .71 apotex 86 introduction .86 company Details .86 products .86 apotriavir .90 financials 91 recent Developments 91 recent Company News 91 recent Litigation .92 aspen Pharmacare .96 introduction .96 company Details .96 products .97 hiv/aids Drugs .97 financials 98 regional Financial Breakdown 98 recent Developments 99 recent Company News 99 aurobindo Pharma .101 World Generic Market Report 2013
  • introduction .101 company Details .101 products .102 financials 105 recent Developments 106 recent Company News 106 recent Litigation .107 cipla 109 introduction .109 company Details .109 manufacturing Facilities .109 products 110 financials .112 recent Developments .113 recent Company News 113 recent Litigation .114 dr Reddy’slaboratories 116 introduction 116 company Details 116 products 117 financials .119 segment Data 120 recent Developments .121 recent Acquisitions .121 recent Company News 121 recent Litigation .123 egis .125 introduction 125 company Details 125 products 126 financials .127 regional Sales Breakdown 128 recent Developments .129 recent Litigation .129 hospira .130 introduction 130 company Details 130 project Fuel 130 manufacturing Facilities 131 products 131 product Development .131 financials .133 results By Region .134 recent Developments .135 recent Agreements .135 recent Company News 135 impax Laboratories 136 World Generic Market Report 2013
  • introduction 136 company Details 136 alliance And Collaboration Agreements 137 products 139 financials 140 sales By Division 140 recent Developments .141 recent Company News 141 recent Litigation .142 krka 147 introduction 147 company Details 147 krka Group Development Strategy 147 products .148 marketing Authorisations .150 prescription Pharmaceuticals 150 financials .150 results By Regions .151 product And Service Groups .153 recent Developments 154 recent Company News 154 lannett .155 introduction .155 company Details .155 products .156 financials 158 recent Developments 159 recent Company News 159 recent Litigation News .160 lupin .161 introduction .161 company Details .161 products .162 financials 164 recent Developments 165 recent Acquisitions .165 recent Company News 165 recent Litigation .166 mylan .168 introduction .168 company Details .168 products .171 financials 178 segment Data 179 recent Developments 180 recent Acquisitions .180 recent Company News 181 World Generic Market Report 2013
  • recent Litigation News .183 par Pharmaceutical Companies .193 introduction .193 company Details .193 products .193 financials 195 segment Data 195 recent Developments 196 recent Acquisitions .196 recent Company News 197 recent Agreements .198 recent Litigation News .199 perrigo .202 introduction .202 company Details .202 products .204 financials 207 segment Sales 207 recent Developments 208 recent Acquisitions 208 recent Company News .209 recent Litigation 209 ranbaxy Laboratories 212 introduction .212 company Details .212 acquisition By Daiichi Sankyo 212 products .213 financials 216 recent Developments 217 recent Company News 217 gedeon Richter .222 introduction .222 company Details .222 products .222 research And Development 223 female Healthcare 224 financials 227 markets – Pharmaceutical Segment .228 recent Developments 231 recent Company News 231 recent Agreements .231 recent Litigation .232 sandoz .233 introduction .233 company Details .233 products .234 financials 238 World Generic Market Report 2013
  • recent Developments 239 recent Acquisitions 239 recent Company News .240 recent Litigation .241 sanofi .244 introduction .244 company Details .244 zentiva .244 medley . 245 kendrick 245 products .245 financials 245 recent Developments 246 recent Company News .246 sawai Pharmaceutical .247 introduction .247 company Details .247 medium-term Business Plan M1 Trust .247 m1 Trust 2015 248 sawai Reviews Japanese Generic Drug Market .248 products .248 new Government Supply Rules, 2006 250 financials 251 recent Developments 252 recent Company News 252 simcere Pharmaceutical .253 introduction .253 company Details .253 products .254 financials 254 recent Developments 255 recent Company News 255 recent Litigation 256 stada Arzneimittel 257 introduction .257 company Details .257 build The Future .257 products .258 biosimilars . 259 financials 259 segment Data .260 geographic Segment Data .261 recent Developments 262 recent Acquisitions 262 recent Company News . 263 sun Pharmaceutical Industries .268 introduction .268 World Generic Market Report 2013
  • company Details .268 group Companies .268 products .271 financials 274 recent Developments 275 recent Company News 275 recent Litigation News .276 teva Pharmaceutical Industries 278 introduction .278 company Details .278 business Strategy 278 organisational Structure 279 products .280 pharmaceutical Production .280 raw Materials For Pharmaceutical Production .281 research And Development 281 generic Products .281 united States .282 europe .282 rest Of The World 282 branded Products .283 copaxone 283 azilect 283 biosimilars .284 financials 288 geographical Breakdown 288 recent Developments 290 recent Acquisitions 290 recent Company News 292 recent Litigation 293 wockhardt .299 introduction .299 company Details .299 products .300 financials 302 recent Developments 304 recent Company News .304 recent Litigation 304 zyduscadila 305 introduction .305 company Details .305 products .306 products Updates For Fy2011/12 .306 financials 308 recent Developments 309 recent Acquisitions 309 recent Company News .309 World Generic Market Report 2013
  • recent Litigation News .310 Market Research Report(http://www.marketresearchreports.biz/) Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.com Website: www.marketresearchreports.biz World Generic Market Report 2013